A Study of CIN-107 in Adults with Primary Aldosteronism

Study identifier:CIN-107-122

ClinicalTrials.gov identifier:NCT04605549

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients with Primary Aldosteronism

Medical condition

Primary Aldosteronism

Phase

Phase 2

Healthy volunteers

No

Study drug

CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing

Sex

All

Actual Enrollment

15

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 08 Mar 2021
Estimated Primary Completion Date: 10 Oct 2024
Estimated Study Completion Date: 10 Oct 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria